Essity AB Series B
Essity AB (publ) develops, produces, and sells hygiene and health products and services in Europe, North and Latin America, Asia, and internationally. The company operates through three segments: Health & Medical, Consumer Goods, and Professional Hygiene. The Health & Medical segment offers incontinence products, wound care, compression therapy, orthopedics, skincare products, wet wipes, wash glo… Read more
Essity AB Series B (0RQD) - Net Assets
Latest net assets as of December 2021: Skr59.87 Billion SEK
Based on the latest financial reports, Essity AB Series B (0RQD) has net assets worth Skr59.87 Billion SEK as of December 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr175.05 Billion) and total liabilities (Skr115.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr59.87 Billion |
| % of Total Assets | 34.2% |
| Annual Growth Rate | 9.08% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.36 |
Essity AB Series B - Net Assets Trend (2017–2021)
This chart illustrates how Essity AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Essity AB Series B (2017–2021)
The table below shows the annual net assets of Essity AB Series B from 2017 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | Skr59.87 Billion | +10.16% |
| 2020-12-31 | Skr54.35 Billion | +0.42% |
| 2019-12-31 | Skr54.12 Billion | +14.82% |
| 2018-12-31 | Skr47.14 Billion | +11.47% |
| 2017-12-31 | Skr42.29 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Essity AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 28.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr51.22 Billion | 85.54% |
| Common Stock | Skr2.35 Billion | 3.92% |
| Other Components | Skr6.31 Billion | 10.54% |
| Total Equity | Skr59.87 Billion | 100.00% |
Essity AB Series B Competitors by Market Cap
The table below lists competitors of Essity AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ralph Lauren Corp Class A
NYSE:RL
|
$13.28 Billion |
|
Affirm Holdings Inc
NASDAQ:AFRM
|
$13.28 Billion |
|
Mr. Cooper Group Inc
NASDAQ:COOP
|
$13.29 Billion |
|
Ovintiv Inc
NYSE:OVV
|
$13.30 Billion |
|
UPM-Kymmene Oyj
PINK:UPMMY
|
$13.27 Billion |
|
Julius Baer Gruppe AG
SW:BAER
|
$13.26 Billion |
|
Ralph Lauren Corp. Cl A
LSE:0KTS
|
$13.26 Billion |
|
Mega Financial Holding Co Ltd
TW:2886
|
$13.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Essity AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 54,352,000,000 to 59,874,000,000, a change of 5,522,000,000 (10.2%).
- Net income of 8,620,000,000 contributed positively to equity growth.
- Dividend payments of 4,741,000,000 reduced retained earnings.
- Other factors increased equity by 1,643,000,000.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr8.62 Billion | +14.4% |
| Dividends Paid | Skr4.74 Billion | -7.92% |
| Other Changes | Skr1.64 Billion | +2.74% |
| Total Change | Skr- | 10.16% |
Book Value vs Market Value Analysis
This analysis compares Essity AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Essity AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.40%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.07%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 2.92x
- Recent ROE (14.40%) is below the historical average (17.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 19.19% | 7.43% | 0.74x | 3.48x | Skr3.89 Billion |
| 2018 | 16.73% | 6.65% | 0.77x | 3.27x | Skr3.17 Billion |
| 2019 | 17.03% | 7.15% | 0.79x | 3.00x | Skr3.80 Billion |
| 2020 | 18.82% | 8.40% | 0.79x | 2.85x | Skr4.79 Billion |
| 2021 | 14.40% | 7.07% | 0.70x | 2.92x | Skr2.63 Billion |
Industry Comparison
This section compares Essity AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Essity AB Series B (0RQD) | Skr59.87 Billion | 19.19% | 1.92x | $13.28 Billion |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |